Skip to main content

IAVI P002

Phase:
I
Status:
Completed
Strategies:
DNA ; Viral Vector - Pox
Candidates:
TBC-M4; ADVAX
Countries:
United Kingdom
Volunteers:
32
Partners:
St. Stephen's Centre, London, UK.

 

Study Summary:

A clinical trial to evaluate the safety and immunogenicity of TBC-M4, an env, gag, tat-rev, and nef-RT MVA HIV vaccine and a prime-boost regimen with ADVAX, an env, gag, nef-tat and pol DNA HIV vaccine and TBC-M4.